Retrospective Analysis of the Epidemiological Change and Determinants of Prognosis of Talaromycosisof Human Immunodeficiency Virus Negative Host in Guangxi
Retrospective Analysis of the Epidemiological Change and Determinants of Prognosis of Talaromycosisof Human Immunodeficiency Virus Negative Host in Guangxi
Through a multi-center large-sample retrospective study, the epidemiological changes of TSM
 in Guangxi have been reviewed, its incidence trend was understood to attract the attention of
 clinicians; the multiple programs of antifungal therapy for HIV-negative host TSM were
 compared in terms of effect on clinical remission rate, effective rate, recurrence rate,
 mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence
 indicators were clarified, and a therapeutic effect evaluation system was established,
 providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously
 the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was
 identified to provide TSM with biological diagnostic indicators. Improve the level of
 understanding and diagnosis and treatment of HIV-negative TSM in the whole area. A
 comprehensive efficacy evaluation system and standard treatment program was established to
 provide a basis for standardized treatment of TSM in HIV-negative hosts. The observational
 indicators included: 2-week all-cause mortality; 24-week all-cause mortality; clinical
 improvement time; level of decrease of fungus in the blood culture medium two weeks before
 treatment; recurrence; appearance of adverse drug reaction at the level 3 and above.
Inclusion Criteria:

 -  Eligible patients were HIV-negative adults who had talaromycosis that was confirmed by
 either microscopy or culture.

 Exclusion Criteria:

 -  patients were HIV-infected adults who had talaromycosis that was confirmed by either
 microscopy or culture.